Sarcomas in hereditary retinoblastoma
- PMID: 23036192
- PMCID: PMC3499233
- DOI: 10.1186/2045-3329-2-15
Sarcomas in hereditary retinoblastoma
Abstract
Children diagnosed with the hereditary form of retinoblastoma (Rb), a rare eye cancer caused by a germline mutation in the RB1 tumor suppressor gene, have excellent survival, but face an increased risk of bone and soft tissue sarcomas. This predisposition to sarcomas has been attributed to genetic susceptibility due to inactivation of the RB1 gene as well as past radiotherapy for Rb. The majority of bone and soft tissue sarcomas among hereditary Rb survivors occur in the head, within the radiation field, but they also occur outside the radiation field. Sarcomas account for almost half of the second primary cancers in hereditary Rb survivors, but they are very rare following non-hereditary Rb. Sarcomas among hereditary Rb survivors arise at ages similar to the pattern of occurrence in the general population. There has been a trend over the past two decades to replace radiotherapy with chemotherapy and other focal therapies (laser or cryosurgery), and most recently, chemosurgery in order to reduce the incidence of sarcomas and other second cancers in Rb survivors. Given the excellent survival of most Rb patients treated in the past, it is important for survivors, their families and health care providers to be aware of the heightened risk for sarcomas in hereditary patients.
Similar articles
-
Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.J Natl Cancer Inst. 2007 Jan 3;99(1):24-31. doi: 10.1093/jnci/djk002. J Natl Cancer Inst. 2007. PMID: 17202110
-
Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up.J Clin Oncol. 2005 Apr 1;23(10):2272-9. doi: 10.1200/JCO.2005.05.054. J Clin Oncol. 2005. PMID: 15800318
-
Osteosarcoma without prior retinoblastoma related to RB1 low-penetrance germline pathogenic variants: A novel type of RB1-related hereditary predisposition syndrome?Mol Genet Genomic Med. 2019 Dec;7(12):e913. doi: 10.1002/mgg3.913. Epub 2019 Sep 30. Mol Genet Genomic Med. 2019. PMID: 31568710 Free PMC article.
-
Risk of Second Tumors in Retinoblastoma Survivors after Ionizing Radiation: A Review.Cancers (Basel). 2023 Nov 9;15(22):5336. doi: 10.3390/cancers15225336. Cancers (Basel). 2023. PMID: 38001596 Free PMC article. Review.
-
Retinoblastoma.Adv Exp Med Biol. 2010;685:220-7. doi: 10.1007/978-1-4419-6448-9_21. Adv Exp Med Biol. 2010. PMID: 20687510 Review.
Cited by
-
Review of Osteosarcoma and Current Management.Rheumatol Ther. 2016 Dec;3(2):221-243. doi: 10.1007/s40744-016-0046-y. Epub 2016 Oct 19. Rheumatol Ther. 2016. PMID: 27761754 Free PMC article. Review.
-
Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.J Clin Oncol. 2014 Oct 10;32(29):3284-90. doi: 10.1200/JCO.2013.54.7844. Epub 2014 Sep 2. J Clin Oncol. 2014. PMID: 25185089 Free PMC article.
-
Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe.J Natl Cancer Inst. 2018 Jun 1;110(6):649-660. doi: 10.1093/jnci/djx235. J Natl Cancer Inst. 2018. PMID: 29165710 Free PMC article.
-
Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.Ophthalmology. 2020 Nov;127(11):1549-1557. doi: 10.1016/j.ophtha.2020.05.024. Epub 2020 May 15. Ophthalmology. 2020. PMID: 32422154 Free PMC article. Review.
-
Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma.Oncol Lett. 2018 Jul;16(1):235-238. doi: 10.3892/ol.2018.8623. Epub 2018 May 3. Oncol Lett. 2018. PMID: 29928406 Free PMC article.
References
-
- Harbour JW. Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol. 2001;119:1699–1704. - PubMed
-
- SEER. Cancer Statistics Review. 2008. [ http://seer.cancer.gov/csr/1975_2008]
LinkOut - more resources
Full Text Sources
Miscellaneous